OpenAI Buys Orchestra Bio to Expand Into Drug Development

On 24 October OpenAI acquired Orchestra Bio, a company using artificial intelligence to improve the drug development process. The deal shows that major technology companies are moving deeper into healthcare and life sciences. HPC can source smaller medical technology, drug development, laboratory and healthcare AI businesses for technology companies and investors.